Insmed Inc (INSM)vsTvardi Therapeutics, Inc. (TVRD)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
TVRD
Tvardi Therapeutics, Inc.
$3.29
-2.08%
HEALTHCARE · Cap: $31.52M
Smart Verdict
WallStSmart Research — data-driven comparison
TVRD leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
TVRD
Avoid26
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : TVRD
The strongest argument for TVRD centers on Price/Book, Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : TVRD
The primary concerns for TVRD are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while TVRD is a value play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
TVRD generates stronger free cash flow (-4M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Tvardi Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering innovative therapies for oncology and other critical medical challenges. Utilizing its proprietary drug discovery platform, Tvardi focuses on the development of small molecule therapies that target protein degradation pathways to offer therapeutic advantages in cancer treatment. Its lead candidate, TVB-2640, is designed to undermine cancer cell survival mechanisms, showcasing the company's dedication to advancing treatment options for patients facing malignancies. With a strong pipeline and a commitment to scientific excellence, Tvardi is well-positioned to transform the cancer therapeutics arena and improve patient outcomes.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?